Coronavirus Notebook: Pfizer Files Paxlovid In EU, France Updates Treatment Advice As Omicron Proliferates

NRx Pharmaceuticals has again filed for a US emergency use authorization for aviptadil, this time for critically ill patients with no other options. The UK has said that there is currently no need to give a second booster vaccine.

Oral Therapy Or Pills Against COVID-19
How effective will COVID-19 treatments be against the Omicron variant? • Source: Alamy

The European Medicines Agency has begun assessing a conditional marketing authorization application (MAA) from Pfizer for its oral antiviral, Paxlovid (PF-07321332 plus ritonavir), for treating mild-to-moderate COVID-19 in adult and adolescent patients who are at high risk of progressing to severe disease.

An opinion on the product from the agency’s human drugs committee, the CHMP, is expected “within weeks” as the committee...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography